Multibagger alert: With nearly 800 per cent jump in net profit, this pharma company has turned investors' wealth multifold!
The pharmaceutical company works with all the top 10 generic pharmaceutical companies in the world.
Laurus Labs Ltd, an S&P BSE 200 company operating in the pharmaceutical industry, has delivered multibagger returns to its shareholders in the last 3 years. During this period, the company’s share price has jumped by 643 per cent, going from Rs 68.93 on 15 July 2019 to Rs 512.55 on 13 July 2022.
The share price performance has been accompanied by a robust financial performance. In the last 3 years, the company’s consolidated topline has grown by 115 per cent. Similarly, the net profits have grown by a stellar 780 per cent!
An investment of Rs 1 lakh in the shares of Laurus Labs three years ago would have turned to Rs 7.43 lakh today.
Laurus Labs is a leading research-driven pharmaceutical and biotechnology company. It operates in three distinct business segments: Generics API, Generics FDF and Synthesis. It works with all the top 10 generic pharmaceutical companies in the world. The pharma company sells its APIs in 56 countries and its major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.
The company is currently trading at a TTM PE of 33.28x against the industry PE of 33.18x. In FY22, the company delivered an ROE & ROCE of 28% and 26%, respectively.
At 12.43 pm, the shares of Laurus Ltd were trading at Rs 520, an increase of 1.45 per cent from the previous day’s closing price of Rs 512.55 on BSE. The stock has a 52-week high & low of Rs 723.55 and Rs 433.20, respectively on BSE.